Work

De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.507

Authors: Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, Antonio Frassoldati, Giulia Valeria Bianchi, Gian Luca De Salvo, Enrico Orvieto, Matteo Curtarello, TomÃ¡s Pascual, Laia Pare, Massimo Ambroggi, Carlo Alberto Giorgi, Gabriella Moretti, Gaia Griguolo, Roberto Vicini, Aleix Prat, Pier Franco Conte

Institutions: University of Padua, Istituto Oncologico Veneto, University of Ferrara, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda Ospedale - Università Padova, Hospital Clínic de Barcelona, Ospedaliera di Piacenza, Santa Maria Nuova Hospital, University of Modena and Reggio Emilia

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2807525481

Cites:

Cited by: 7

Related to: 10